Merck & Company Inc (MRK)vsCatheter Precision Inc. (VTAK)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
VTAK
Catheter Precision Inc.
$0.18
+6.06%
HEALTHCARE · Cap: $758,350
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 3476088% more annual revenue ($66.57B vs $1.92M). MRK leads profitability with a 4.8% profit margin vs 0.0%. VTAK earns a higher WallStSmart Score of 43/100 (D).
MRK
Hold36
out of 100
Grade: F
VTAK
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Intrinsic value data unavailable for VTAK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Reasonable price relative to book value
Revenue surging 380.7% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : VTAK
The strongest argument for VTAK centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 380.7% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : VTAK
The primary concerns for VTAK are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while VTAK is a hypergrowth play — different risk/reward profiles.
VTAK carries more volatility with a beta of 0.48 — expect wider price swings.
VTAK is growing revenue faster at 380.7% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
VTAK scores higher overall (43/100 vs 36/100) and 380.7% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Catheter Precision Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company is headquartered in Fort Mill, South Carolina.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?